(June 23, 2017, 1:39 PM EDT) -- WILMINGTON, Del. — A drug maker was ordered June 20 by a jury empaneled before U.S. Judge Leonard P. Stark of the District of Delaware to pay GlaxoSmithKline PLC (GSK) $235.5 million in damages in connection with its marketing of generic Coreg as a treatment for chronic heart failure (CHF) (GlaxoSmithKline PLC v. Teva Pharmaceuticals USA Inc., No. 14-877, D. Del.)....